摘要
【目的】本研究旨在探讨PLC delta1在上皮性卵巢肿瘤中的表达及其临床意义。【方法】采用免疫组化方法,检测PLC delta1在223例上皮性卵巢肿瘤(183例卵巢癌和对照组40例交界性卵巢肿瘤)组织芯片中的表达;结合患者的临床资料,分析PLC delta1的表达与上皮性卵巢癌的关系。【结果】在有效检测的197例上皮性卵巢肿瘤标本中,大多数(25例,80.6%)交界性肿瘤呈现正常表达,而在卵巢癌中,多数(91例54.8%)肿瘤出现PLC delta1的过度表达,两者存在显著差异(P<0.0001);而且PLC delta1在卵巢癌中表达与肿瘤的临床分期、患者年龄有显著的相关性(P<0.0001)。【结论】PLC delta1在卵巢癌组织中的过度表达与肿瘤的恶性进展密切相关,可能是未来检测卵巢癌的一种有价值的新肿瘤标志物。
【Objective】 To investigate the expression of PLC delta 1 in epithelial ovarian tumor and its clinical significance. 【Method】 Examination of PLC delta 1 expression in the tissue microarray among 223 cases of epithelial ovarian tumor (including 183 cases of ovarian cancer and the control group ,40 of borderline ovarian tumor),using immunohistochemistry method. Subsequent analysis was conducted to reveal the relationship between PLC delta 1 expression and the occurrence of epithelial ovarian cancer. 【Results】 Among 197 valid samples,most of the borderline tumor cases (25 samples,80.6%) indicated normal expression of PLC delta 1; most of the ovarian cancer cases (91 samples,54.8%),on the other hand,indicated overexpression of PLC delta 1. The study also found a significant difference in PLC delta 1 expression (P〈 0.000 1) between the two types of cases. Also,there is a significant correlation between the PLC delta 1 expression in the ovarian cancer cases and their clinical stages,as well as the age of the patients (P〈 0.000 1). 【Conclusion】 The overexpression of PLC delta 1 in the ovarian cancer tissue is closely related to tumor malignancy,suggesting that PLC delta 1 could be another effective marker for the diagnosis of ovarian cancer.
出处
《中山大学学报(医学科学版)》
CAS
CSCD
北大核心
2010年第4期540-544,共5页
Journal of Sun Yat-Sen University:Medical Sciences
基金
广东省科技计划项目(2004B35001004)